Vasogen to Present at Adams Harkness' Inflammatory Disease Company
Showcase & Panel Discussion on December 14, 2005
Toronto, Ontario - December 08, 2005
Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, today announced that David Elsley, President and CEO of Vasogen, has been invited to present at the "Trends in Inflammatory Disease" investor conference hosted by Adams Harkness on Wednesday, December 14, 2005, at the Omni Berkshire Place in New York City.
Guillermo Torre-Amione, MD, PhD, Medical Director, The Methodist DeBakey Heart Center, has also been selected as an expert panelist for the conference. Dr. Torre-Amione is the U.S. Principal Investigator for the 2,400-patient pivotal phase III ACCLAIM trial of Vasogen’s Celacade™ technology targeting the chronic inflammation underlying chronic heart failure. Vasogen recently announced that the final patient assessments in the ACCLAIM trial are expected to be completed next month, following which preparations for database lock and data analysis will commence.
About Vasogen
Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The Company’s lead product, the Celacade™ technology, is currently in the final stages of two pivotal phase III clinical trials designed to support regulatory approval in North America and commercialization in North America and Europe. The 550-patient phase III SIMPADICO trial, which was closed out early in August 2005, is a 50-center North American study designed to further investigate the use of Celacade technology to improve intermittent claudication, a debilitating symptom associated with peripheral arterial disease. The 2,400-patient phase III ACCLAIM trial is a 176-center international study that is designed to further investigate the use of Celacade technology to reduce the risk of death and hospitalization in patients with advanced chronic heart failure. Vasogen is also developing a new class of drugs for the treatment of neuro-inflammatory disorders. VP025, which has completed phase I clinical development, is the lead product candidate from this new class of drugs.
